1. |
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat, 2004, 11(2):97-107.
|
2. |
Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J (Engl), 2009, 122(1):3-4.
|
3. |
Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J]. J Clin Oncol, 2004, 22(5):927-934.
|
4. |
Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology, 2003, 37(6):1320-1328.
|
5. |
贾杰, 林锋. 拉米夫定预防化疗诱发乙型肝炎病毒再活动的初步研究[J]. 中华肝脏病杂志, 2004, 12(10):628-629.
|
6. |
Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J]. Gastroenterology, 2003, 125(6):1742-1749.
|
7. |
Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area:a case-control study[J]. Jpn J Cancer Res, 2002, 93(5):471-477.
|
8. |
Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma[J]. Ann Hematol, 2008, 87(6):475-480.
|
9. |
European Association For The Study Of The Liver. EASL clinical practice guidelines:management of chronic hepatitis B[J]. J Hepatol, 2009, 50(2):227-242.
|
10. |
Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J]. MMWR Recomm Rep, 2008, 57(RR/8):1-20.
|
11. |
Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors[J]. J Med Virol, 2000, 62(3):299-307.
|
12. |
Lee R, Vu K, Bell CM, et al. Screening for hepatitis B surface antigen before chemotherapy:current practice and opportunities for improvement[J]. Curr Oncol, 2010, 17(6):32-38.
|
13. |
Hwang J, Fisch M, Zhang H, et al. Predictors of hepatitis B screening among patients with cancer[J]. J Clin Oncol, 2011, 29(Suppl 4):180.
|
14. |
中华医学会血液学分会, 中国抗癌协会淋巴瘤专业委员会, 中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J]. 中华血液学杂志, 2013, 34(11):988-993.
|
15. |
Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma:a cost-effectiveness analysis[J]. J Clin Oncol, 2012, 30(26):3167-3173.
|
16. |
Wang Y, Luo XM, Yang D, et al. Testing for hepatitis B infection in prospective chemotherapy patients:a retrospective study[J]. World J Gastroenterol, 2013, 19(6):923-930.
|
17. |
Hwang J, Fisch M, Zhang H, et al. Hepatitis B screening and positivity prior to chemotherapy[J]. J Clin Oncol, 2010, 28(Suppl 15):9008.
|
18. |
Méndez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy[J]. Liver Int, 2011, 31(3):330-339.
|
19. |
Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J]. Cancer, 2007, 109(7):1360-1364.
|
20. |
Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma[J]. Haematologica, 2006, 91(4):554-557.
|
21. |
Liang X, Bi S, Yang W, et al. Reprint of:epidemiological serosurvey of hepatitis B in china:declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2013, 31(Suppl 9):J21-J28.
|
22. |
Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology, 2007, 45(2):507-539.
|
23. |
Ji D, Cao J, Hong X, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive:a multicenter retrospective study[J]. Eur J Haematol, 2010, 85(3):243-250.
|
24. |
Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 2009, 27(4):605-611.
|
25. |
Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma[J]. Int J Hematol, 2009, 90(1):13-23.
|
26. |
Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells[J]. Semin Oncol, 2003, 30(1 Suppl 2):3-8.
|
27. |
Wilson WH, Gutierrez M, O'connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma:a preliminary report of dose-adjusted EPOCH-R[J]. Semin Oncol, 2002, 29(Suppl 2):41-47.
|
28. |
Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin[J]. Blood, 2001, 97(5):1392-1398.
|
29. |
Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20(IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J]. Cancer Biother Radiopharm, 1997, 12(3):177-186.
|
30. |
Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases:meta-analysis and examination of FDA safety reports[J]. Ann Oncol, 2011, 22(5):1170-1180.
|
31. |
Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy:a meta-analysis[J]. J Clin Virol, 2013, 57(3):209-214.
|
32. |
Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma[J]. Ann Hematol, 2004, 83(1):58-60.
|
33. |
Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP[J]. Ann Hematol, 2004, 83(12):769-774.
|
34. |
Wang YH, Fan L, Wang L, et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy[J]. Support Care Cancer, 2013, 21(5):1265-1271.
|
35. |
Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy[J]. Med Oncol, 2012, 29(2):1237-1241.
|
36. |
Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients:a meta-analysis[J]. Liver Int, 2008, 28(1):28-38.
|
37. |
Lau GK. Hepatitis B reactivation after chemotherapy:two decades of clinical research[J]. Hepatol Int, 2008, 2(2):152-162.
|